<DOC>
	<DOC>NCT02485548</DOC>
	<brief_summary>This study is a multicenter phase Ⅲ trial. The objective is to compare the efficacy and toxicity of cisplatin plus raltitrexed or 5-fluorouracil in concurrence with IMRT for patients with locoregionally advanced head and neck squamous cell cancer.</brief_summary>
	<brief_title>Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer</brief_title>
	<detailed_description>The objective is to compare the efficacy and toxicity of cisplatin plus raltitrexed or 5-fluorouracil in concurrence with IMRT for patients with locoregionally advanced head and neck squamous cell cancer.</detailed_description>
	<mesh_term>Neoplasms, Squamous Cell</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Pathologically confirmed untreated head and neck squamous cell cancer patients 1870 years Clinical stage: T34N03M0 or T14N13M0 Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 10mg/dL Renal function: Cr ≤ 1.25×UNL Hepatic function: BIL ≤ 1.5×UNL, ALT/AST ≤ 2.5×UNL ECOG ≤ 1 Woman and man of childbearing age must adopt contraception With written consent Malignant history Pregnant or lactating women With other severe diseases (blood, liver ,kidney or heart diseases) Subjects not suitable for chemoradiotherapy Without written consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>